Upside case
Bull case
—
The bull case requires both strong earnings delivery and the market pricing BBIO more generously than it does today.
Analysis OverviewBuyUpdated Jun 18, 2026
BridgeBio Pharma, Inc. (BBIO) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
26
analysts
24 bullish · 0 bearish · 26 covering BBIO
Strong Buy
0
Buy
24
Hold
2
Sell
0
Strong Sell
0
Consensus Target
$105
+57.8% vs today
Scenario Range
— – —
Model bear to bull value window
Coverage
26
Published analyst ratings
Valuation Context
—
Forward P/E · Market cap $13.0B
BBIO price targets
Three scenarios for where BBIO stock could go
Current
~$66
Confidence
50 / 100
Updated
Jun 18, 2026
Market caseClosest to today
Base case
—
The base case reflects analyst consensus expectations — steady delivery without requiring a major catalyst or re-rating.
Stress case
Bear case
—
The bear case reflects a scenario where earnings shortfalls or multiple compression combine to materially reduce the stock from its current level.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
BridgeBio Pharma, Inc.
BBIO · NASDAQHealthcareBiotechnologyDecember year-end
BridgeBio Pharma is a biopharmaceutical company focused on discovering and developing precision medicines for genetic diseases. It generates revenue primarily through drug development partnerships and potential future product sales — though currently in pre-revenue stage with multiple programs in clinical trials. The company's key advantage is its efficient hub-and-spoke operating model that allows rapid development of targeted therapies for rare genetic conditions.
Market Cap
$13.0B
Revenue TTM
$580M
Net Income TTM
-$726M
Net Margin
-125.2%
BBIO Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
33%Exceptional
12 quarters tracked
Revenue Beat Rate
50%Exceptional
vs consensus estimates
Avg EPS Surprise
-2.1%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 0 of 4Q3 2025
EPS
$-0.95/$-0.83
Revenue
$111M/$108M
Q4 2025
EPS
$-0.95/$-0.88
Revenue
$121M/$148M
Q1 2026
EPS
$-1.00/$-0.71
Revenue
$154M/$147M
Q2 2026
EPS
$-0.84/$-0.68
Revenue
$195M/$178M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $-0.95/$-0.83 | -14.5% | $111M/$108M | +2.3% |
| Q4 2025 | $-0.95/$-0.88 | -8.0% | $121M/$148M | -18.5% |
| Q1 2026 | $-1.00/$-0.71 | -40.2% | $154M/$147M | +5.0% |
| Q2 2026 | $-0.84/$-0.68 | -23.8% | $195M/$178M | +9.2% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$732M
+26.3% YoY
FY2
$931M
+27.2% YoY
EPS Outlook
FY1
$-0.88
+76.3% YoY
FY2
$-0.45
+49.5% YoY
Trailing FCF (TTM)-$454M
FCF Margin: -78.3%
Next Earnings
August 4, 2026
Expected EPS
$-0.63
Expected Revenue
$220M
BBIO beat EPS estimates in 0 of 4 tracked quarters. Mixed delivery makes the upcoming report a key data point for re-rating.
BBIO Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $502M
Product Mix
Latest annual revenue by segment or product family
Product
72.2%
+9453.6% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
Segment breakdown not available for this company.
Product is the largest disclosed segment at 72.2% of FY 2025 revenue, up 9453.6% YoY.
BBIO Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Relative Valuation
Benchmark comparison across market, sector, and history below.
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
BBIO
-17.5x
vs
S&P 500
24.4x
172% discount
vs Healthcare Trailing P/E
BBIO
-17.5x
vs
Healthcare
22.1x
179% discount
vs BBIO 5Y Avg P/E
Today
-17.5x
vs
5Y Average
—
Benchmark unavailable
Forward PE
—
S&P 500
18.8x
—
Healthcare
18.3x
—
5Y Avg
—
—
Trailing PE
-17.5x
S&P 500
24.4x
-172%
Healthcare
22.1x
-179%
5Y Avg
—
—
PEG Ratio
—
S&P 500
1.66x
—
Healthcare
1.59x
—
5Y Avg
—
—
EV/EBITDA
—
S&P 500
15.2x
—
Healthcare
14.2x
—
5Y Avg
—
—
Price/FCF
—
S&P 500
20.7x
—
Healthcare
18.5x
—
5Y Avg
—
—
Price/Sales
25.9x
S&P 500
3.1x
+736%
Healthcare
2.6x
+881%
5Y Avg
25.5x
+1%
Dividend Yield
—
S&P 500
1.91%
—
Healthcare
1.50%
—
5Y Avg
—
—
| Metric | BBIO | S&P 500 | Healthcare | 5Y Avg BBIO |
|---|---|---|---|---|
| Forward PE | — | 18.8x | 18.3x | — |
| Trailing PE | -17.5x | 24.4x-172% | 22.1x-179% | — |
| PEG Ratio | — | 1.66x | 1.59x | — |
| EV/EBITDA | — | 15.2x | 14.2x | — |
| Price/FCF | — | 20.7x | 18.5x | — |
| Price/Sales | 25.9x | 3.1x+736% | 2.6x+881% | 25.5x |
| Dividend Yield | — | 1.91% | 1.50% | — |
BBIO trades above S&P 500 benchmarks on 1 of 2 measured multiples — is elevated on some multiples, but competitive on others — a mixed valuation picture.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolBBIO Financial Health
Verdict
Stressed
Key financial metrics for BBIO are shown below.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$580M
Revenue Growth
TTM vs prior year
+355.2%
Gross Margin
Gross profit as a share of revenue
93.8%
Operating Margin
Operating income divided by revenue
-98.4%
Net Margin
Net income divided by revenue
-125.2%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$-3.73
Free Cash Flow (TTM)
Cash generation after capex
-$454M
FCF Margin
FCF as share of revenue — the primary cash quality signal
-78.3%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
-524.0%
ROA
Return on assets, trailing twelve months
-66.2%
Cash & Equivalents
Liquid assets on the balance sheet
$570M
Net Debt
Total debt minus cash
$2.2B
Debt Serviceability
Net debt as a multiple of annual free cash flow
—
ROE
Return on equity, trailing twelve months
—
Shareholder Returns
How capital is returned to owners
Total shareholder yield
0.4%
Dividend
—
Buyback
0.4%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$48M
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Declining as buybacks retire shares
196M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageBBIO Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 18, 2026
High Risk
Financial Distress
Negative Earnings Yield and Altman Z-score indicate significant financial distress and potential insolvency risk.
High Risk
Cash Burn
High growth potential from its new heart drug is offset by high cash burn and significant financial risks.
Medium
Pipeline Execution
Investors should track pipeline execution, particularly the planned NDA submission for encaleret in the first half to the FDA, followed by an EMA filing.
Medium
Earnings Uncertainty
Market reaction to earnings uncertainty led to a 15.24% drop as investors reacted to growing uncertainty around its upcoming fourth quarter and full year 2025 results.
Lower
Valuation Concerns
Despite a negative DCF value and Graham Number, the market has priced it with a Forward P/E suggesting optimism for future earnings.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why BBIO Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 18, 2026
Positive Phase 3 trial results
Interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 met efficacy endpoints, indicating strong clinical progress.
Strong Attruby U.S. launch
BridgeBio Pharma's Attruby has shown a strong U.S. launch, contributing to favorable competitive dynamics and revenue growth.
Favorable analyst sentiment
Analysts maintain a Buy rating on BBIO, citing strong clinical and commercial performance as key drivers.
Upcoming expanded trial results
Expanded results from the Phase 3 FORTIFY trial are anticipated, which could further validate BBP-418's efficacy and market potential.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
BBIO Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$66.27
52W Range Position
59%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$39.65
+67.1% from the low
52-Week High
$84.94
-22.0% from the high
1 Month
+1.45%
3 Month
-5.49%
YTD
-15.3%
1 Year
+65.7%
3Y CAGR
+58.9%
5Y CAGR
+1.6%
10Y CAGR
+9.2%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
BBIO vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
—
vs 17.2x median
Peer median unavailable
Revenue Growth
+26.3%
vs +15.1% median
+74% above peer median
Net Margin
-125.2%
vs -81.0% median
-55% below peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
BBI BBIO BridgeBio Pharma, Inc. | $13.0B | — | +26.3% | -125.2% | Buy | +57.8% |
KYM KYMR Kymera Therapeutics, Inc. | $7.4B | — | +23.7% | -612.2% | Buy | +24.5% |
ARR ARRY Array Technologies, Inc. | $1.2B | 11.0x | +15.1% | -5.6% | Buy | +22.5% |
RCU RCUS Arcus Biosciences, Inc. | $2.4B | — | +35.0% | -156.4% | Buy | +27.5% |
PRA PRAX Praxis Precision Medicines, Inc. | $8.2B | — | +14.7% | — | Buy | +106.9% |
VRT VRTX Vertex Pharmaceuticals Incorporated | $114.9B | 23.4x | +11.0% | 35.4% | Buy | +22.7% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
BBIO Dividend and Capital Return
BBIO returns 0.4% annually — null% through dividends and 0.4% through buybacks.
Dividend UnknownFCF Unknown
Total Shareholder Yield
0.4%
Dividend + buyback return per year
Buyback Yield
0.4%
Dividend Yield
—
Payout Ratio
—
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.00
Growth Streak
Consecutive years of dividend increases
0Y
3Y Div CAGR
—
5Y Div CAGR
—
Ex-Dividend Date
—
Payment Cadence
—
0 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$48M
Estimated Shares Retired
728.5K
Approx. Share Reduction
0.4%
Shares Outstanding
Current diluted share count from the screening snapshot
196M
FAQ
7 questionsBBIO Investor Questions
Common questions answered from live analyst data and company financials.
01Is BridgeBio Pharma, Inc. (BBIO) stock a buy or sell in 2026?
BridgeBio Pharma, Inc. (BBIO) is rated Buy by Wall Street analysts as of 2026. Of 26 analysts covering the stock, 24 rate it Buy or Strong Buy, 2 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $105, implying +57.8% from the current price of $66.
02What is the BBIO stock price target for 2026?
The Wall Street consensus price target for BBIO is $105 based on 26 analyst estimates. The high-end target is $157 (+136.9% from today), and the low-end target is $83 (+25.2%).
03Is BridgeBio Pharma, Inc. (BBIO) stock overvalued in 2026?
Forward earnings data for BBIO is not currently available. Review the valuation table above for trailing P/E, EV/EBITDA, and price-to-sales comparisons against market and sector benchmarks.
04What are the main risks for BridgeBio Pharma, Inc. (BBIO) stock in 2026?
The primary risks for BBIO in 2026 are: (1) Financial Distress — Negative Earnings Yield and Altman Z-score indicate significant financial distress and potential insolvency risk. (2) Cash Burn — High growth potential from its new heart drug is offset by high cash burn and significant financial risks. (3) Pipeline Execution — Investors should track pipeline execution, particularly the planned NDA submission for encaleret in the first half to the FDA, followed by an EMA filing. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is BridgeBio Pharma, Inc.'s revenue and earnings forecast?
Analyst consensus estimates BBIO will report consensus revenue of $732M (+26.3% year-over-year) and EPS of $-0.88 (+76.3% year-over-year) for the upcoming fiscal year. The following year, analysts project $931M in revenue.
06When does BridgeBio Pharma, Inc. (BBIO) report its next earnings?
BridgeBio Pharma, Inc. is expected to report its next earnings on approximately 2026-08-04. Consensus expects EPS of $-0.63 and revenue of $220M. Over recent quarters, BBIO has beaten EPS estimates 33% of the time.
07How much free cash flow does BridgeBio Pharma, Inc. generate?
BridgeBio Pharma, Inc. (BBIO) had a free cash outflow of $454M in free cash flow over the trailing twelve months — a free cash flow margin of 78.3%. BBIO returns capital to shareholders through and share repurchases ($48M TTM).